Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

AGM Trading Update

10 Jul 2025 07:00

RNS Number : 4225Q
Dr. Martens PLC
10 July 2025
 

10 July 2025

Dr. Martens plc - AGM Trading Update

Trading in line with expectations; FY26 guidance unchanged

 

Dr. Martens plc will hold its AGM at 09.30am today at 1-11 Hawley Crescent, Camden, London, NW1 8NP, and also provides the following update.

Trading since the start of this financial year has been in line with expectations and all guidance for FY26 remains unchanged. On a regional basis, we have continued to see positive trading in our Americas Direct to Consumer ("DTC") channel, driven by full price sales, particularly in Retail. Our EMEA DTC business remains more variable, with our UK business in particular continuing to experience a challenging trading backdrop. Our APAC business continues to show good growth, with a particularly strong performance in South Korea driven by our well-established shoes category here.

Looking forward, the Autumn/Winter order books globally are healthy. The EMEA order book is up year-on-year, whilst the Americas order book is broadly in line year-on-year and importantly is based on a much wider product range than previously. As ever, our performance will be H2-weighted, particularly from a profit perspective.

We are focused on embedding our new consumer-first Levers for Growth strategy, which we outlined at our results on 5 June and which builds on the work undertaken in FY25 to stabilise the business. The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us. It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model. Further details on our early progress in these areas will be shared at our first half results in November.

 

 

Enquiries

 

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager beth.fionda@drmartens.com

 

Press

Sodali & Co

Ludo Baynham-Herd

Oliver Banks drmartens@client.sodali.com

+44 207 250 1446

 

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSAFIUEISEDW
Date   Source Headline
1st Aug 202511:51 amRNSTotal Voting Rights
28th Jul 20258:53 amRNSDirector/PDMR Shareholding
14th Jul 20253:08 pmRNSDirector/PDMR Shareholding
10th Jul 202510:58 amRNSResult of 2025 AGM
10th Jul 20257:00 amRNSAGM Trading Update
4th Jul 20251:56 pmRNSTotal Voting Rights
17th Jun 202510:00 amRNSDirector/PDMR Shareholding
17th Jun 20259:00 amRNSAnnual Financial Report
12th Jun 20254:13 pmRNSDirector/PDMR Shareholding
5th Jun 20257:00 amRNSFinal Results
2nd Jun 20252:05 pmRNSBlock listing Interim Review
30th May 202510:52 amRNSTotal Voting Rights
27th May 20258:45 amRNSDirector Declaration
14th May 20252:20 pmRNSDirector/PDMR Shareholding
1st May 20254:02 pmRNSTotal Voting Rights
16th Apr 20254:00 pmRNSDirector/PDMR Shareholding
9th Apr 20253:00 pmRNSDirector/PDMR Shareholding
31st Mar 20259:38 amRNSTotal Voting Rights
26th Mar 202510:00 amRNSDirector/PDMR Shareholding
12th Mar 20252:26 pmRNSDirector/PDMR Shareholding
28th Feb 202511:01 amRNSTotal Voting Rights
12th Feb 20254:35 pmRNSDirector/PDMR Shareholding
12th Feb 20257:00 amRNSAppointment of Non-Executive Directors
31st Jan 202510:36 amRNSTotal Voting Rights
27th Jan 20257:00 amRNSQ3 FY25 Trading Statement
15th Jan 20256:14 pmRNSDirector/PDMR Shareholding
2nd Jan 202512:02 pmRNSTotal Voting Rights
20th Dec 20243:07 pmRNSHolding(s) in Company
13th Dec 202411:54 amRNSDirector/PDMR Shareholding
12th Dec 20247:00 amRNSBlock Listing Application
2nd Dec 202410:43 amRNSBlock listing Interim Review
2nd Dec 202410:10 amRNSTotal Voting Rights
28th Nov 20247:01 amRNSConfirmation of new CEO start date
28th Nov 20247:00 amRNSHalf-year Report
12th Nov 20243:56 pmRNSDirector/PDMR Shareholding
31st Oct 20243:23 pmRNSTotal Voting Rights
15th Oct 20243:19 pmRNSDirector/PDMR Shareholding
2nd Oct 20241:55 pmRNSDirector/PDMR Shareholding
30th Sep 202410:24 amRNSTotal Voting Rights
26th Sep 20242:00 pmRNSTransaction by PCA of PDMR
25th Sep 20247:00 amRNSHolding(s) in Company
24th Sep 202410:53 amRNSDirector/PDMR Shareholding
23rd Sep 20244:31 pmRNSHolding(s) in Company
12th Sep 20243:13 pmRNSDirector/PDMR Shareholding
30th Aug 20243:19 pmRNSTotal Voting Rights
27th Aug 202411:58 amRNSDirector/PDMR Shareholding
20th Aug 20243:48 pmRNSDirector/PDMR Shareholding
12th Aug 202411:30 amRNSHolding(s) in Company
31st Jul 20243:43 pmRNSTotal Voting Rights
12th Jul 202412:42 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.